Samsung Bioepis Breaks Down Biosimilar Experiences In Europe And US
'Both Markets Require Rigorous Standards For Approval'
Samsung Bioepis reiterated that the US pharma market is “the most fragmented and the most complicated market in the world” as it discussed its biosimilar fortunes in Europe.
